Dr. Bashir Lawal is a prolific cancer biologist and immunogenomicist whose work sits at the interface of translational oncology, functional genomics, and computational biology. With a robust background in drug discovery and immune-oncology, his research deciphers cryptic genomic rearrangements and transcriptional programs that underlie therapy resistance and immune evasion in aggressive cancers. In addition to his laboratory excellence, Dr. Lawal has led the discovery and preclinical validation of multiple synthetic small-molecule drug candidates, such as NLOC-015A and BC-N102, targeting immune escape, cell cycle deregulation, and EGFR-related oncogenic axes. He has successfully translated bioinformatic predictions into wet-lab validations.
Dr. Lawal holds a PhD in Cancer Biology from Taipei Medical University, and currently serves as a Postdoctoral Associate at the UPMC Hillman Cancer Center and University of Pittsburgh. His academic record is punctuated by numerous competitive awards and honors, including the Hillman Fellowship for Innovative Cancer Research, the United State Foundation for Women Wellness Research Fellowship, the Hillman Cancer Center Poster Award (1st Place), and the TMU-Alumni Thesis Award. He has published over 120 peer-reviewed articles, many in high-impact journals such as Frontiers in Immunology, Cancers, American Journal of Cancer Research, and Biomedicine, accruing citations for his influential work in cancer immunogenomics and translational therapeutics.
In addition to his prolific research output, Dr. Lawal has held editorial and reviewer roles for over a dozen international journals, including Cancers, Frontiers in Oncology, Phytomedicine, and Plos One. He currently serves as Editor-in-Chief of Biomed Natural and Applied Sciences and as a Guest Editor for Biomedicine’s special issue on integrative genomic analysis and pharmaco-informatics. He is a member of leading societies including the American Association for Cancer Research (AACR), the Society for Immunotherapy of Cancer (SITC), and the Hillman Clinician-Scientist Program.
Dr. Lawal has mentored trainees, delivered invited talks internationally—including seminar series at Taipei Medical University and the UPMC Hillman Cancer Center—and is deeply committed to the advancement of cancer therapeutics and immunogenomics research. His global collaborations, consistent funding success, editorial leadership, and translational innovation clearly position him as a leader in his field. In recognition of his exceptional research impact, international standing, and demonstrated leadership, Dr. Bashir Lawal is highly deserving of elevation to the rank of Fellow (FIASS) of the International Academy of Science and Society.
